Deciphera Pharmaceuticals, Inc.
DCPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DCPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2024.
Tracking 4 pipeline candidates · 15 clinical trials for Deciphera Pharmaceuticals, Inc..
Run Deciphera Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Deciphera Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
9.3 months
D/E 0.33 · 6% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Deciphera Pharmaceuticals, Inc.'s lead drug candidate?
Deciphera Pharmaceuticals, Inc.'s most advanced tracked candidate is dcc-3009 (Phase 1/Phase 2) for Gastrointestinal Stromal Tumor (GIST).
Who is the CEO of Deciphera Pharmaceuticals, Inc.?
Massachusetts April is the chief executive officer of Deciphera Pharmaceuticals, Inc. (DCPH).
What therapeutic areas does Deciphera Pharmaceuticals, Inc. focus on?
Deciphera Pharmaceuticals, Inc. develops therapies across Oncology, Immunology, Nephrology, Gastroenterology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.